MELT-300 Pivotal Phase 3 Program Topline Readout Expected in Q4 2024 NASHVILLE, Tenn. --(BUSINESS WIRE)--Apr. 2, 2024-- Melt Pharmaceuticals, Inc. (“Melt”), a clinical‑stage pharmaceutical company developing novel approaches for procedural sedation, today announced the completion of its Series B

NASHVILLE, Tenn. --(BUSINESS WIRE)--Jan. 3, 2024-- Melt Pharmaceuticals, Inc. (“Melt”), a clinical‑stage pharmaceutical company developing novel approaches for procedural sedation, today provided a corporate update. The Company previously announced that MELT-300 achieved the primary sedation